Gapping up
In reaction to earnings/guidance:
- AYI +5.2%, WELL +1.3% (guidance update)
Other news:
- AUTL +14.2% (has entered into an agreement with Bristol Myers Squibb)
- POSH +12.9% (to be acquired for $17.90 per share in cash)
- RIVN +8.3% (reports Q3 production and delivery data; remains on track to deliver on its 25000 annual production guidance)
- BLKB +6.8% (Clearlake Capital discloses 18.4% stake; firm may push for review of strategic alternatives)
- SITM +5% (delivers precision timing solution for Tesla Dojo AI Supercomputer)
- HUT +4.7% (provides September production and operations update)
- DNA +4.5% (acquires Circularis to strengthen capabilities in cell and gene therapy)
- WES +4.4% (WES and OXY to explore carbon capture systems)
- AMRX +4.3% (announces commercial launch of ALYMSYS)
- GSM +4.1% (to restart silicon metal facility in South Africa)
- BLUE +3.9% (collaborates with Real Endpoints Marketplace to help scale delivery of a first-of-its-kind value-based contract for one-time gene therapy)
- OLN +3.1% (expects to cease methylene chloride and chloroform production at its Germany facility by 3Q23)
- GLPG +3% (says EMA committee has adopted a positive opinion on Jyseleca)
- LUMN +2.6% (Brightspeed begun operations as a new company following the completion of the previously announced acquisition of incumbent local exchange carrier assets and associated operations across 20 states from LUMN by Apollo-managed funds)
- ALGN +2.5% (introduces latest iTero-exocad Connector software release)
- DINO +2.4% (entered into another Stock Purchase Agreement with REH Company)
- LILM +1.9% (stock offering)
- OXY +1.9% (WES and OXY to explore carbon capture systems)
Analyst comments:
- COMM +6.2% (upgraded to Outperform from Neutral at Credit Suisse)
- BK +3.1% (upgraded to Buy from Neutral at Citigroup)